Year: 2025
Type: article
Abstract: T cell receptor-engineered T cell (TCR-T) therapy has emerged as a promising approach in cancer immunotherapy, with applications in both hematologic malignancies and solid tumors, by targeting tumor-specific antigens. However, several challenges hinder its widespread practical application. First, the complexity and specificity of tumor antigen selection limit treatment efficacy. Second, challenges in optimizing TCR affinity and overcoming tumor-induced immunosuppression limit the further refinement of therapeutic strategies. Third, the clinical application of current TCR-T products is constrained by limited patient response rates, potential safety concerns, and high manufacturing costs. Recent research progress includes advancements in high-throughput antigen screening technologies, such as single-cell RNA sequencing and peptide-MHC multimer platforms, which have improved the identification of neoantigens and TCRs with high affinity and specificity. Additionally, innovative strategies like combination therapies with immune checkpoint inhibitors (e.g., PD-1 blockers) and STING agonists have shown potential to enhance TCR-T cell efficacy and persistence in the tumor microenvironment. Future breakthroughs may involve the development of universal TCR-T platforms and gene-editing technologies (e.g., CRISPR/Cas9) to reduce costs and improve scalability. In conclusion, while TCR-T therapy faces significant challenges, its potential to revolutionize cancer treatment is undeniable. Addressing issues such as tumor heterogeneity, immune evasion, and manufacturing efficiency will be critical for its broader clinical adoption.
Source: Theoretical and Natural Science
Author: Zihan Wang
Institution: Beijing University of Technology
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W4410418156